Skip to main content

Table 1 Baseline characteristics

From: Impaired energetics and normal myocardial lipids in rheumatoid arthritis and systemic lupus erythematosus: a phosphorous and proton magnetic resonance spectroscopy and cardiovascular magnetic resonance study

 

Controls N=12

RA N=16

SLE N=13

P value

Female sex, n (%)

8 (67)

10 (63)

13 (100)

0.05

Age, years

49 ± 15

51 ± 13

43 ± 9

0.18

Hypertension, n (%)

0

3 (19)

2 (16)

-

Diabetes, n (%)

0

0

1 (8)

-

Hyperlipidaemia, n (%)

0

3 (19)

0

-

BMI, kg/m2

24 ± 3

25 ± 3

27 ± 5

0.12

Chloroquine, n (%)

N/A

11 (69)

11 (85)

-

Methotrexate, n (%)

N/A

15 (94)

1 (8)

-

Prednisolone, n (%)

N/A

2 (13)

9 (69)

-

Leflunomide, n (%)

N/A

3 (19)

1 (8)

-

Sulfasalazine, n (%)

N/A

3 (19)

0

-

Azathioprine, n (%)

N/A

0

4 (31)

-

Rituximab, n (%)

N/A

2 (13)

1 (8)

-

DAS28-CRP

N/A

5 ± 1

N/A

-

SLEDAI (median, IQR)

N/A

N/A

7 (4-11)

-

ESR, mm/hr (median, IQR)

N/A

7 (5-10)

10 (4-16)

-

CRP, mg/L (median, IQR)

1 (1-1)

5 (2-7)

4 (2-6)

<0.001

Duration of disease, years (median, IQR)

N/A

11 (7-14)

13 (6-16)

-

Duration of DMARDs, years (median, IQR)

N/A

7 (5-11)

8 (3-11)

-

  1. Continuous data are mean ± SD unless otherwise indicated. Categorical data are frequency (percent) unless otherwise indicated. BMI, body mass index; CRP, C-reactive protein; DAS28-CRP (rheumatoid arthritis disease activity index incorporating 28 swollen and tender joint count as well as the C-reactive protein); ESR, erythrocyte sedimentation rate; IQR, interquartile range; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index